Michael Hutton


Michael Hutton joined Lilly as Chief Scientific Officer for Neurodegenerative Disease in 2009 and was appointed UK Site Scientific Leader in 2012. He is based at Erl Wood and leads drug discovery for Alzheimer’s Disease, Parkinson’s Disease and fronto-temporal dementia.

Prior to joining Lilly, Dr Hutton worked at Merck and at the Mayo Clinic Jacksonville (FL, USA) as Professor of Neuroscience. During his time at Mayo, Dr Hutton’s team played a major role in determining the causes of fronto-temporal dementia with the discovery of mutations in tau and progranulin and the mechanism by which these lead to neurodegeneration.


Fill in the form and will be in touch with you shortly.

Google reCaptcha: Invalid site key.

Why a form?
Your message is important to us so thank you for filling in our form – it will be received by the intended recipient and you will receive a reply via email. We’ve introduced a form to better protect our team from website scraping generated spam but hope that real people with real messages will still take the time to complete it.